Sector News

Amneal Pharma to buy Actavis Australia’s generic pharma business

April 2, 2015
Life sciences
Amneal Pharmaceuticals Pty Ltd and Actavis Australia Pty Ltd, a subsidiary of Actavis plc, have signed a binding letter of intent which provides that Amneal intends to acquire substantially all of Actavis’ in-country generic pharmaceuticals business for an agreed price, subject to completion of confirmatory due diligence and definitive agreements.
 
Financial terms of the agreement are not available. However, both sides have agreed to work expeditiously to complete the transaction with the goal of preventing disruption of supply to existing purchasers of Actavis’ products.
 
Actavis will continue to supply the Australian market with these high quality generic medicines on the PBS and fulfill supply commitments for all hospital tenders until this transition is complete.
 
Importantly, for the non-generic business, Actavis will continue to promote and distribute branded medicines in the portfolio including but not limited to products such as Actonel and Oxytrol. A dedicated GP sales team will be maintained with the responsibility for supporting GPs and specialists who prescribe primary care products, including Actonel. Actavis will also continue to supply Botox, eye-care products and all other heritage Allergan products.
 
Amneal Pharmaceuticals LLC is a global supplier of generic pharmaceuticals, vertically-integrated across the entire supply chain from R&D to finished goods. 
 
Actavis plc, headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Actavis is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
 

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.